# Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

> **NCT04953325** · PHASE4 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 270 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated COVID-19 Vaccine
- **BIOLOGICAL:** 23-valent pneumococcal polysaccharide vaccine
- **BIOLOGICAL:** Inactivated Hepatitis A Vaccine

## Key facts

- **NCT ID:** NCT04953325
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-09
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04953325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04953325, "Immunogenicity and Safety of an Inactivated COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04953325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*